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Abstract
Chronic granulomatous disease (CGD) is an inherited immunodeficiency disease caused by defects in leukocyte NADPH
oxidase. Various inherited defects in one of the membrane-bound components of NADPH oxidase, gp91-phox, cause X-
linked (X91) CGD. Analysis of three patients with X91 CGD revealed that different mechanisms of molecular quality control
lead to the common phenotype of absence of mature membrane-bound NADPH oxidase complex in leukocytes. In the first
patient, aberrant intron splicing created a premature stop codon. However, the mutant mRNA was degraded prematurely,
which prevented the production of truncated protein. In the second patient, a frameshift mutation with the potential to
generate a gp91-phox polypeptide, with an aberrant and elongated C-terminus, led to barely detectable levels of gp91-phox,
even though the reported functional domains of the protein appeared unaffected. In the third patient, a point mutation
created a single amino acid change in the predicted FAD-binding site of gp91-phox. Although gp91-phox was detectable with
Western blotting, no cytochrome b558 was expressed on the cell surface. These analyses showed that molecular quality control
machinery plays an important role in the pathogenesis of CGD, not only in the X910 but also in the X913 form of this X-
linked disease. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Chronic granulomatous disease (CGD) is a heredi-
tary immunode¢ciency caused by defects in the phag-
ocyte nicotinamide adenine dinucleotide phosphate
reduced (NADPH) oxidase. NADPH oxidase is com-
posed of cell membrane-bound gp91-phox and p22-
phox, which together form £avocytochrome b558, and
the cytoplasmic proteins p40-phox, p47-phox and
p67-phox. Failure of the enzyme to generate reactive
oxygen species (ROS), including superoxide and hy-
drogen peroxide, leads to compromised microbicidal
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activity and hence recurrent infections from an early
age [1].
A wide variety of mutations have been reported in
CGD patients in the genes encoding gp91-, p22-,
p67-, and p47-phox [2^4]. Approx. 65% of CGD
cases are inherited in an X-linked manner, and are
caused by mutations in CYBB, the gene encoding the
gp91-phox subunit of £avocytochrome b558. Three
forms of X-linked CGD, X910, X913 and X91,
have been reported based on the expressed amount
of gp91-phox [2]. The wide distribution of CGD mu-
tations in NADPH oxidase genes provides a unique
opportunity to investigate the functional and struc-
tural role of di¡erent domains in this enzyme com-
plex. Some mutations cause CGD by disrupting do-
mains that are critical for the enzyme activity of
NADPH oxidase, while others inhibit the transcrip-
tion or translation of the a¡ected genes [4]. Addi-
tional disease-causing mutations may initiate the
cell’s quality control mechanisms and lead to prema-
ture destruction of the gene products.
Leukocytes, like other cells, use various mecha-
nisms to identify and remove abnormal newly syn-
thesized molecules, in order to prevent their incorrect
function in the cell [5]. Products of the mutated genes
are often detected early in the biosynthetic process
and degraded prematurely. When mutations a¡ect
the gene products to the extent that this quality con-
trol machinery is initiated, elimination of the partic-
ular gene products by degrading enzymes may con-
tribute to the functional de¢ciency in a¡ected cells.
We investigated the molecular defects in three
newly identi¢ed patients with X-linked CGD (X91
CGD). We found that molecular quality control
mechanisms in the nucleus or endoplasmic reticulum
(ER) monitor the production of proteins destined for
plasma membrane and endocytic organelles. This
molecular monitoring may play an important role
in the de¢ciency of NADPH oxidase function in
these X-CGD patients.
2. Materials and methods
2.1. Case reports
2.1.1. Patient 1
Patient 1 was admitted at age 2 years and 3
months with fever, severe pain and swelling and sub-
cutaneous nodules on his left forearm, which was
fractured in a fall 2 weeks previously. Shortly after
birth he presented with recurrent perianal ¢stulas
and abscesses, and at the age of 14 months was di-
agnosed with right tibial osteomyelitis caused by Ser-
ratia marcescens. He completely recovered after de-
bridement and antimicrobial therapy at another
hospital. At admission, he weighed 11 kg and had
a body length of 82 cm, both of which fell below the
tenth percentile curve of the normal population.
Physical examination revealed multiple small ab-
scesses with redness and tenderness, over the cheeks
and all four extremities. Radiographic ¢ndings
showed osteolytic lesions with periosteal reaction,
which were compatible with osteomyelitis of the
left ulna. Debridement was performed and the tissue
culture revealed Salmonella group D. Five months
later, this patient was readmitted with bilateral sub-
mandibular lymphadenitis caused by S. marcescens.
The diagnosis of CGD was established using a nitro
blue tetrazolium (NBT) dye reduction test and £ow
cytometric measurement of granulocyte respiratory
burst [6,7].
2.1.2. Patient 2
Patient 2 was a 3.5-month-old infant when he was
hospitalized due to prolonged diarrhea and recurrent
cellulitis of the right foot at the site of a previous
intravenous injection. The cellulitis did not amelio-
rate after strong antibiotic treatment at another hos-
pital and a bone scan revealed osteomyelitis of the
right foot. Due to signi¢cant hepatomegaly, abdomi-
nal sonography was performed and di¡used multiple
nodular lesions (about 1 cm each), compatible with
liver abscesses, were revealed. Repeated blood and
wound cultures showed S. marcescens and Entero-
bacter cloacae. As an immunode¢ciency was sus-
pected, a panel of immunological tests was per-
formed. An NBT test and £ow cytometric analysis
of granulocyte respiratory burst con¢rmed the diag-
nosis of CGD. The patient was treated with wound
debridement and intravenous antibiotics for 2 months
in the hospital. An episode of pneumonia compli-
cated with pleural empyema occurred 6 months after
the ¢rst admission. Microbiological cultures revealed
Aspergillus fumigatus and Klebsiella pneumoniae. His
condition improved after 2 months of antifungal and
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antibacterial treatment. He was then put on prophy-
lactic antibiotics with regular follow-up at the out-
patient clinic.
2.1.3. Patient 3
Patient 3, a 20-month-old male, was admitted to
the hospital with prolonged fever and recurrent
perianal abscesses and ¢stulas. The patient had suf-
fered from chronic diarrhea since he was 4 months of
age and recurrent perianal abscesses, which devel-
oped into ¢stulas, since he was 6 months of age.
Axillary lymphadenopathy, sized 2U2 cm, was noted
since he was 5 months of age. Repeated bacterial
culture from the perianal lesions revealed Enterobac-
teriaceae species. Marked hepatosplenomegaly was
noted in physical examination. An abdominal CAT
scan showed multiple hypodense lesions in the spleen
from 2 cm to 4 cm in diameter. Hemisplenectomy
was performed and granuloma formation was noted
in the spleen tissue. Microbiological studies showed
the growth of Paecilomyces variotti. An NBT test
and £ow cytometric analysis of granulocyte respira-
tory burst con¢rmed the diagnosis of CGD. His con-
dition stabilized after oral antifungal treatment for
1 year. Oral prophylaxis with trimethoprim^sulfame-
thoxazole has prevented severe infection for more
than 2 years since his ¢rst hospitalization.
2.2. Monoclonal antibodies
Antibodies speci¢c for gp91-phox and gp22-phox,
mAb 48 and 449, respectively, and polyclonal anti-
bodies against p47-phox and p67-phox were kindly
provided by Dr. D. Roos (CLB, Amsterdam, The
Netherlands). Another monoclonal antibody,
mAb58.1, against gp91-phox was a gift from Dr. J.
Burritt (Montana State University, MT, USA) and
was used for immunoprecipitation in metabolic label-
ing and pulse chase experiments. A monoclonal anti-
body, AF8, against calnexin was provided by Dr.
M.B. Brenner (Harvard University, MA, USA). A
polyclonal antibody against actin was purchased
from Sigma. A monoclonal antibody, 7D5, speci¢c
for cytochrome b558 was a generous gift from Dr. M.
Nakamura (Nagasaki University, Japan). 3C7 mAb,
speci¢c for Giardia, and W6/32 mAb, speci¢c for
MHC class I, were purchased from ATCC (Rock-
ville, MD, USA).
2.3. Lymphocyte transformation with Epstein^Barr
virus
Mononuclear leukocytes isolated from 5 ml of ve-
nous blood by Ficoll-Hypaque centrifugation (Phar-
macia) were cultured in growth medium (RPMI 1640
supplemented with 20% FCS, 1% glutamine, 2 Wg/ml
cyclosporin and 1% penicillin and streptomycin) and
15% culture supernatant of Epstein^Barr virus (EBV)
secreting cell line B95-8. Phytohemagglutinin-L
(PHA-L, Murex, Chatillon, France; 45 Wg/ml) was
added to the culture medium on the third day. The
concentration of cyclosporin was decreased to 1 Wg/
ml by adding an equal volume of cyclosporin-free
medium after 1 week. The transformed lymphocytes
proliferated and formed cell clusters after 3^4 weeks.
EBV-transformed B lymphocytes express an
NADPH oxidase identical to that found in phago-
cytic leukocytes [8], therefore biochemical and cellu-
lar analyses were performed using these cells through
this study.
2.4. Single strand conformational polymorphism
(SSCP) analysis
Genomic DNA (100 Wg) extracted from leukocytes
and primer pairs spanning the 5P £anking region and
all 13 exons of the CYBB gene were used for poly-
merase chain reaction (PCR). The PCR products
were puri¢ed and analyzed with PAGE at 12‡C as
previously reported [9].
2.5. Reverse transcriptase (RT)-PCR
Total RNA was isolated from EBV-transformed
lymphocytes using the Gstract Total RNA Isolation
Kit (MBI, So. San Francisco, CA, USA). Two mi-
crograms of total RNA was used for RT-PCR. M-
MLV reverse transcriptase with random hexamer
primers (Promega) was used to make cDNA. Taq
DNA polymerase (MBI) with speci¢c primer pairs
was used for PCR. The PCR products were resolved
on 1.6% agarose gel and visualized with ethidium
bromide. A pair of primers that span exon 7 was
used to detect alternative splicing in patient 1; sense
primer: 5P-TGTTGGCAGGCATCACTGGAGTT-
GTCATCACGC-3P ; antisense primer: 5P-GAACA-
CATCTTCACTGGCAGTGCCAAAGGGCCCATC-3P.
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A pair of primers downstream from exon 7 was used
to quantify the mRNA. The sequences were as fol-
lows: sense: 5P-AATGCTTGTGGCTGTGATAAG-
CAGGAGTTTCAA-3P ; antisense: 5P-AGCATTAT-
TTGAGCATTTGGCAGCACAACCCACA-3P. For
semi-quantitative purposes, PCR were ¢rst per-
formed at di¡erent cycle numbers. A cycle number
in which the PCR product increased exponentially
were selected for each pair of primers. cDNA tem-
plate that produced equivalent amounts of L-actin
product was used for each reaction.
2.6. Ampli¢cation of genomic DNA and analytic
sequencing
For patient 1, the intronic primer pair 5P-AA-
TTTAATTTCCTATTACTAAATGATCTGGAC-3P
(sense) and 5P-AGACACAGGTTAAAGATTG-3P
(antisense) spanning exon 7 of the CYBB gene was
used for PCR ampli¢cation and sequencing of ge-
nomic DNA. For patient 2, the intronic primer
pair 5P-CGGGAAATTCACCTACCTGC-3P (sense)
and 5P-AGCATTATTTGAGCATTTGGC-3P (anti-
sense) spanning exon 13 of CYBB was used. For
patient 3, the intronic primers 5P-CCATATGACAC-
TAAAAAGGC-3P (sense) and 5P-CGATGCGGA-
TATGGATACT-3P (antisense) were used, based on
the genomic sequence spanning exon 9 of the CYBB
gene. PCR products were puri¢ed with a QIA quick
PCR Puri¢cation Kit (Qiagen) and sequenced in
both directions using an ABI Prism Automatic Se-
quencer (PE Biosystems) at the NCKU Clinical Re-
search Center.
2.7. Immunoprecipitation and Western blot analysis
EBV-transformed human lymphocytes (1U107)
were lysed with 1 ml of lysis bu¡er containing Tris
bu¡ered saline (TBS, pH 7.6), 1% Triton X-100
(TX100), 1 mM phenylmethylsulfonyl £uoride
(PMSF), 8 mM iodoacetamide (IAA), and Complete
protein inhibitor cocktail (Boehringer, Mannheim,
Germany) by shaking for 1 h at 4‡C. Lysates pre-
pared from 5U105 cells were used for each analysis.
For analysis on whole cell lysates, the lysates were
boiled in sample bu¡er (TBS with 10% glycerol, 3%
SDS) without reducing agents for 8 min and resolved
by SDS^PAGE on 10.5% acrylamide gels as de-
scribed [10]. For co-immunoprecipitation experi-
ments with anti-calnexin mAb, the cells were lysed
with lysis bu¡er containing 1% NP-40 instead of
TX100. The lysates were incubated with 2 Wl of
mAb containing ascites followed by incubation with
100 Wl of protein G-Sepharose (Pharmacia, Piscat-
away, NJ, USA). The immunoprecipitates were
washed ¢ve times with TBS with 1% NP-40, eluted
with sample bu¡er containing 10% glycerol, 3% SDS
by boiling for 3 min and resolved by SDS^PAGE
before Western blotting. For Western blotting anal-
ysis, proteins were electroblotted to PVDF mem-
brane (Millipore, Bedford, MA, USA), and probed
with primary mAb, followed by a secondary anti-
body (goat anti-mouse HRP-labeled antibody, Up-
state Biotechnology, Lake Placid, NY, USA). The
blot was then visualized with a chemiluminescent
substrate (ECL, Amersham) and then exposed to
autoradiography ¢lm [11].
2.8. Cell surface labeling of proteins
1U107 EBV-transformed human lymphocytes sus-
pended in PBS were incubated with 10 Wl E-Z link
biotin (10 mg/ml, Pierce) for 30 min, washed three
times with PBS and lysed in 1 ml lysis bu¡er con-
taining Tris bu¡ered saline (TBS, pH 7.6), 1%
TX100, 1 mM PMSF, 8 mM IAA, and Complete
protein inhibitor cocktail (Boehringer) by shaking
for 1 h at 4‡C. The immunoprecipitates were re-
solved on 10.5% SDS^PAGE and visualized with
streptavidin^HRP and ECL reagents (Amersham
Pharmacia).
2.9. Endoglycosidase digestion and analysis
N-Glycosidase F (PNGase F) and endoglycosidase
H (Endo-H) were purchased from New England Bio-
labs (Beverly, MA, USA). For total lysate analysis,
50 Wg protein were digested with 2000 U Endo-H or
PNGase F at 37‡C for 2 h before SDS^PAGE and
Western blot analysis.
2.10. Metabolic labeling and pulse chase analysis
EBV-transformed lymphocytes (1U107 for each
condition) were labeled with 0.3 mCi of
[35S]methionine for 1 h. The labeled cells were either
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lysed after washing (0 h) or cultured in normal me-
dium for 5 h before lysis. The lysates were then im-
munoprecipitated with an anti-gp91-phox mAb
(mAb58.1) or anti-calnexin mAb (AF8), analyzed
with SDS^PAGE and visualized with autoradiogra-
phy.
2.11. Cell surface staining and £ow cytometric analysis
Flow cytometric analysis was performed on leuko-
cytes as previously described [12] using the Epics XL/
MCL £ow cytometer (Beckman-Coulter). Lympho-
cytes were analyzed after gating based on cell size
and granularity. Primary and secondary antibodies
were used at saturating concentrations. Isotype
matched irrelevant mAb (3C7) was used as a nega-
tive control and W6/32 antibody (mouse anti-human
MHC class I) was used as a positive control. The
mean £uorescence intensity (MFI) of negative con-
trols was consistently less than 10 £uorescence units.
3. Results
3.1. Mutations at three di¡erent locations of
CYBB gene were identi¢ed in patients with
X-linked CGD
Three di¡erent mutations in the CYBB gene were
identi¢ed in three pediatric patients with X91 CGD
using SSCP analysis and automatic sequencing of
genomic DNA (Fig. 1). Using genomic DNA as
the template, we found a GT to AT transition at
the splice donor site of intron 7 after sequence anal-
ysis of PCR products that included all exons and
intron^exon junctions. This mutated sequence is crit-
ical for correct exon splicing of nascent mRNA. In
patient 2, we found a deletion of G1691, located 31
nucleotides upstream from the stop codon. This
frameshift mutation abrogates the original stop
codon and changes the C-terminal 11 amino acids
of gp91-phox to a mutant sequence of 16 amino
acids. In patient 3, a C to T transition at nucleotide
1024 was identi¢ed. This mutation predicts a change
from histidine to tyrosine at residue 338, which is
located in the putative FAD-binding domain of
gp91-phox [13]. For each of the three patients, mu-
tant and normal sequences were observed in the
mothers, con¢rming them all to be carriers of the
X-linked defects (Fig. 1). The mutations identi¢ed
in patients 1 and 2 are novel, while the C1024T tran-
sition in patient 3 has been observed previously [14].
3.2. mRNA transcript of CYBB gene with a mutation
in intron splice site was severely decreased
Mutations at the splice donor site, such as the one
found in patient 1, generally lead to an aberrant or
ine⁄cient mRNA splicing process. To quantify the
CYBB mRNA present in normal leukocytes and the
leukocytes from these patients, we performed a semi-
quantitative RT-PCR measurement of mRNA using
L-actin as a control. A pair of primers based on
CYBB sequence downstream from the patient 1 mu-
tation site (exon 7) was used for the PCR. The
amount of CYBB mRNA in leukocytes from patient
1 was only 24.9% of the level in normal control leu-
kocytes, while no di¡erence in the CYBB mRNA
amount was observed in leukocytes from patient 2
and patient 3 (Fig. 2a). Another pair of upstream
primers was used to perform the semi-quantitative
RT-PCR with similar results (data not shown). These
results demonstrated that for patient 1, a markedly
decreased amount of the mutant mRNA exists in the
cell, presumably due to instability of the mRNA in-
duced by the mutation.
Next, we examined more closely the expressed
CYBB mRNA in patient 1 and the gene carrier
mother, using RT-PCR (Fig. 2b). We found that a
679 bp gene product was made, as expected as a
combination of sequences from exons 6, 7, and 8,
in normal controls. An aberrant product, sized 540
bp, was observed in reactions using the cDNA of
patient 1 as the template, consistent with the absence
of exon 7. Sequence analysis con¢rmed that the am-
pli¢ed fragment was the product of splicing between
exon 6 and exon 8 (not shown). Although both the
normal gene product and the aberrant gene product
were detected in the carrier mother, the normal prod-
uct was 10.5 times more abundant than the aberrant
one (Fig. 2b, lane 2).
3.3. A frameshift mutation on the C-terminus of gp91-
phox leads to a marked decrease in protein level
Using Western blotting, we analyzed leukocyte ly-
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sates from CGD patients and normal controls for the
CYBB gene product, gp91-phox, along with other
components of the NADPH oxidase (Fig. 3). L-Actin
was used as an internal control. In consistence with
the decreased amount and smaller size of CYBB
mRNA in patient 1, gp91-phox protein in leukocytes
from this patient was almost undetectable. Interest-
ingly, we found that the gp91-phox protein also was
almost undetectable in patient 2, who had a deletion
of nucleotide 1691, which predicts a polypeptide
chain elongated by ¢ve amino acids. This result dem-
onstrated that even though leukocytes from patient 2
expressed normal amounts of gp91-phox mRNA, the
aberrant C-terminal sequence causes a marked de-
crease in the mutant protein. The level of gp91-
phox in patient 3 was 65% of normal. P22-phox in
patient 3 was also more abundant than in patients 1
and 2, but less than in the normal control (relative
intensity: patient 1, 43%; patient 2, 48%; patient 3,
84%). Levels of the cytoplasmic components of
NADPH oxidase, p47-phox and p67-phox, were com-
parable in all three patients and the normal control.
3.4. Lack of cell surface expression of cytochrome
b558 on leukocytes of patient 3
Even though signi¢cant amounts of gp91-phox
were detected in leukocytes from patient 3 (Fig. 3),
cell surface staining with mAb 7D5, speci¢c for an
extracellular epitope of gp91-phox [15], showed that
no cytochrome b558 could be detected on the surface
of the patient’s leukocytes (Fig. 4a, right panel). Leu-
kocytes from a normal control were stained with the
same antibody (Fig. 4a, left panel).
Cell surface labeling with biotinylation followed by
immunoprecipitation with an anti-gp91-phox anti-
body (mAb 48) was performed to be compared
with the results of cell surface staining and £ow cy-
tometric analysis. While a distinct broad band with
an apparent molecular mass of 80^100 kDa was ob-
served in the immunoprecipitate from the normal
control, no similar bands were observed in the im-
munoprecipitates from patient 1 and patient 3 (Fig.
4b). These results suggested that the gp91-phox pro-
Fig. 2. Mutant mRNA, missing exon 7 due to a defective in-
tron splice site, was decreased in abundance in leukocytes from
patient 1 and the carrier mother. (a) Semi-quantitative RT-PCR
with a primer pair downstream from the mutation site, exon 7,
was performed to measure the relative amount of CYBB
mRNA in all three patients. L-Actin mRNA in the same sam-
ples was measured for comparison. The histogram on the bot-
tom shows the ratios of the intensity of CYBB product and L-
actin product in all three patients (P1, P2 and P3). (b) Mutant
and normal cDNA were detected with RT-PCR using a primer
pair that spans exon 7. While a PCR product of 679 bp was
detected in normal control (NC), a shorter product of 540 bp
was found in patient 1. In the gene carrier (C), both a normal-
sized product and a shortened product were present. The signal
intensity of the normal sized and the shorter products were
91.3% and 8.7% of the total signal, respectively.
6
Fig. 1. Mutations were identi¢ed in three X-linked CGD patients in di¡erent regions of CYBB gene. Mutations in the CYBB gene
were localized by SSCP and identi¢ed by automatic sequencing of the genomic DNA and cDNA, as described in Section 2. In patient
1 (upper panel), a point mutation at the splice donor site of intron 7 from GT to AT (arrow) was identi¢ed. In patient 2 (middle pan-
el), a deletion of a G at nucleotide 1691 (arrow) was found. In patient 3, a point mutation at nucleotide 1024 from G to T was de-
tected. In each panel, the sequencing results of the patient, the gene carrier mother, and a normal subject are shown.
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tein detected in whole cell lysate of patient 3 is likely
to be distributed di¡erently in the leukocytes.
3.5. A point mutation in the predicted FAD-binding
site of gp91-phox leads to ER retention and
defective protein maturation
Leukocyte lysates from all three X91 CGD pa-
tients were analyzed by SDS^PAGE and immuno-
blotting with a mAb speci¢c for gp91-phox. As pre-
viously observed, a smear comprised of multiple
bands, ranging in size from 60 kDa to 130 kDa,
was detected in the leukocytes from patient 3 and
control subjects (Fig. 3). When comparing the
gp91-phox protein from patient 3 and the normal
control, we found a 60^65 kDa band that is more
apparent in patient 3. We suspected this band repre-
sented an immature intracellular form of gp91-phox,
and consequently performed further biochemical
analysis of the protein.
Molecular chaperons, including calnexin, may play
important roles in preventing abnormal proteins
from exiting the ER. The ER chaperon calnexin
binds to nascent glycoproteins during their folding
and assembly [16,17]. To dissect the maturation sta-
tus of gp91-phox in normal and CGD leukocytes, we
performed co-immunoprecipitation experiments with
an anti-calnexin mAb, AF8, to analyze the proteins
that are associated with calnexin in patient 3. Cells
from patient 1, which express very little gp91-phox,
were also included as a negative control. Immuno-
precipitated calnexin was probed with anti-calnexin
mAb as an internal control (Fig. 5, middle panel). As
shown in Fig. 5 (upper left panel), gp91-phox co-
sedimented with calnexin in both patient 3 and the
normal control. Comparable to the immunoblot of
whole cell lysate in Fig. 3, gp91-phox resolved as a
smear ranging from 60 to 130 kDa. The 60^65 kDa
Fig. 4. Lack of leukocyte cell surface gp91-phox protein in pa-
tient 3. (a) Cell surface staining of leukocytes from normal con-
trol (left) and patient 3 (right) was performed with mAb 7D5
(red pro¢le) and an isotype matched irrelevant mAb (3C7,
black pro¢le) followed by staining with a FITC-labeled goat
anti-mouse Ig secondary antibody. The stained cells were then
analyzed by £ow cytometry. (b) Cell surface biotinylation fol-
lowed by immunoprecipitation with mAb 48 (anti-gp91-phox,
upper panel) and W6/32 (anti-mature MHC class I, lower pan-
el). Leukocytes from a normal control (NC), patient 1 (P1) and
patient 3 (P3) were used for analysis. The experiment was re-
peated with similar results.
Fig. 3. NADPH oxidase components in the leukocytes of CGD
patients. Whole cell lysates of leukocytes from the three CGD
patients and a normal control were resolved on a SDS^PAGE
gel, electroblotted to PVDF membrane and probed with anti-
bodies against gp91-phox, p22-phox, p67-phox, p47-phox, and
L-actin (from top to bottom). Equivalent amounts of L-actin
were detected in each lane. The mAb speci¢c for gp91-phox de-
tected molecules with the molecular mass range 60^130 kDa
(bracket). An apparent 60^65 kDa band in patient 3 is marked
with an arrow (gp65). The relative amount of gp91-phox and
p22-phox in comparison with the normal control is shown on
the bottom. Similar results were observed in three independent
experiments.
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protein, which was apparent in the total cell lysate of
patient 3, was detected in calnexin co-immunoprecip-
itates from both the normal control and patient 3
(arrow). These speci¢c bands for gp91-phox were not
detected in the lane using cell lysates of patient 1 for
immunoprecipitation (third lane, left upper panel).
Two bands sized around 100 kDa and 125 kDa ap-
peared in all three lanes of normal control, patient 3
and patient 1. These appear to be cross-reactive pro-
tein species co-sedimented with calnexin because they
appeared in the lane of patient 1 at comparable in-
tensity. These 100 kDa and 125 kDa cross-reactive
bands appear to be recognized by the anti-gp91 mAb
with glycan-dependent epitopes and were no longer
detected after deglycosylation with Endo-H and
PNGase F. The calnexin-associated gp91-phox, how-
ever, was still recognized after Endo-H and PNGase
F digestion and was resolved as a 55 kDa band after
treatment of either enzyme (Fig. 5, right panel). P22-
phox was detected in the co-sedimentation with cal-
nexin in patient 1, patient 3 and the normal control
(Fig. 5, lower panel). These data suggested that the
60^65 kDa protein, referred to as gp65 in previous
reports, represents one of the immature forms of
gp91-phox that are associated with ER chaperons.
This immature form is present in both normal sub-
jects and in patient 3 in the ER. This form becomes
the apparent component in patient 3 because protein
maturation is blocked.
To further address the role of these calnexin-asso-
ciated immature glycoproteins in the intracellular
pool of gp91-phox, we tested the Endo-H sensitivity
of gp91-phox in whole cell lysate of patient 3 and a
Fig. 6. Most gp91-phox in patient 3 is sensitive to Endo-H di-
gestion and immature gp91-phox associates longer with calnex-
in. (a) The gp91-phox protein without (left) and with (right)
Endo-H digestion from leukocyte lysates of a normal control
(NC), patient 3 (P3), and patient 1 (P1) was analyzed with im-
munoblot followed by probing with anti-gp91-phox mAb.
Equivalent L-actin was detected in each sample analyzed (mid-
dle panel). The ratios of the intensity of signals in the molecu-
lar mass range (65^130 kDa, marked with a bracket) of gp91-
phox with and without Endo-H digestion are shown in the his-
togram. These results are representative of three experiments.
(b) Pulse chase experiments on EBV-transformed lymphocytes
from a normal control and patient 3. After 1 h of labeling with
[35S]methionine, the cells were either lysed after washing (0 h)
or cultured in normal medium for 5 h before lysis. The lysates
were then immunoprecipitated with an anti-gp91-phox mAb
(mAb58.1) or anti-calnexin mAb (AF8) and analyzed on SDS^
PAGE. This analysis was repeated with similar results.
Fig. 5. Immature forms of gp91-phox associated with calnexin
in both patient 3 and normal control. From the leukocyte ly-
sate of a normal control (NC), patient 3 (P3), and patient 1
(P1), immunoprecipitation was performed with mAb speci¢c for
calnexin. Immunoprecipitates were resolved on SDS^PAGE,
electroblotted to PVDF membrane and probed with mAb spe-
ci¢c for gp91-phox. In contrast to the results with whole cell ly-
sates in Fig. 3, a 60^65 kDa band (gp65) was observed in the
lanes of both normal control and patient 3 (arrow, upper left
panel). The gp91-phox co-sedimented with calnexin was reduced
to a 55 kDa band after Endo-H or PNGase F digestion (right
panel). The blot also was probed with anti-calnexin mAb (mid-
dle panel) and anti-p22-phox (lower panel).
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normal control. In contrast to gp91-phox from the
normal control, which was mostly Endo-H resistant,
gp91-phox from leukocytes of patient 3 was more
sensitive to Endo-H deglycosylation (Fig. 6a). After
Endo-H treatment, most proteins in the 60^130 kDa
smear, including the 60^65 kDa band, were reduced
to a 55 kDa protein. A lesser proportion of the leu-
kocyte gp91-phox was deglycosylated in the normal
control (28% decrease in normal controls vs. 80%
decrease in patient 3). In some experiments in which
we used mAbs to detect gp91-phox in lysates, in ad-
dition to the 60^130 kDa smear that is speci¢c for
gp91-phox, we detected two bands of around 80 kDa
and 120 kDa. These bands were resistant to Endo-H
and are likely to be cross-reactive species, as they are
also detected in comparable amounts in cells of pa-
tient 1 (lanes 3 and 6, Fig. 6a), which express very
little gp91-phox (shown in Fig. 3).
In order to investigate the time course of the in-
teraction between this newly synthesized immature
gp91-phox (gp65) and calnexin, we performed pulse
chase experiments on EBV-transformed lymphocytes
from a normal control and patient 3. After 1 h of
labeling with [35S]methionine, the cells were either
lysed after washing or cultured in normal medium
for 5 h before lysis. The lysates were then immuno-
precipitated with an anti-gp91-phox mAb or anti-cal-
nexin mAb and analyzed on SDS^PAGE. Gp65 co-
immunoprecipitated with calnexin from normal con-
trol lymphocytes was apparent after 1 h labeling but
was barely detectable after 5 h chase (Fig. 6b, upper
panel). In contrast, gp65 was still apparent in the
calnexin co-precipitation after a 5 h chase (Fig. 6b,
lower panel). These analyses were in accordance with
the proposition that in patient 3, immature gp91-
phox associates longer with calnexin and remains
Endo-H sensitive. The immature gp91-phox species,
although present in signi¢cant amounts, was pre-
vented from being expressed on the cell surface by
quality control mechanisms that retain the chaperon-
associated mutant protein in the ER.
4. Discussion
Flavocytochrome b558, a heterodimer comprised of
gp91-phox and p22-phox, is the central part of the
respiratory burst NADPH oxidase, which is impor-
tant for microbicidal activity of phagocytic leuko-
cytes [3,18]. Various mutations in the CYBB gene,
which encodes the gp91-phox, disrupt the function
of leukocyte NADPH oxidase and cause X-linked
CGD. In this study, we investigated the molecular
mechanisms underlying three newly diagnosed cases
of X91 CGD. Our results shed light on the role of
molecular control machinery in the pathogenesis of
CGD.
To prevent aberrant molecules from wasting pre-
cious resources in the cell, various mechanisms func-
tion to detect mutant molecules at the level of
mRNA, nascent peptide or protein complex. This
machinery also protects cells from potential domi-
nant negative functional disruption of the normal
allele by the mutant gene products [5], and may ac-
count for the lack of abnormality in carriers of many
autosomal recessive diseases. On the other hand, this
molecular monitoring system may exclude the ex-
pression of some mutated gene products with poten-
tially intact functional domains, possibly aggravating
the severity of the disease. In CGD, which primarily
a¡ects phagocytes, degradation mechanisms in leu-
kocytes should participate in this process [19]. In
patient 1, aberrant intron splicing created a prema-
ture stop codon. However, the mutant mRNA ap-
peared to be degraded prematurely in the patient,
preventing the production of functionless, truncated
protein. In patient 2, a frameshift mutation with the
potential to generate a gp91-phox polypeptide with
an aberrant and elongated (by ¢ve amino acids) C-
terminus, leads to barely detectable levels of gp91-
phox, even though the reported functional domains
of the protein appeared una¡ected. In patient 3, a
point mutation creates a single amino acid change
(His to Tyr) in the predicted FAD-binding site of
gp91-phox. Although gp91-phox was detectable with
Western blotting, no cytochrome b558 was expressed
on the cell surface. The molecular quality control
mechanisms appear to work by detecting the aber-
rant gene products and either preventing the trans-
lation by decreasing the mRNA (as in patient 1) or
degrading the newly synthesized peptides shortly
after they are made (as in patient 2). Quality control
machinery thus excludes the expression of these mu-
tant molecules.
The mutation in patient 3 has been reported as
causing either X910 [3] or X913 [2] CGD. This might
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be due to the fact that although gp91-phox can be
detected in the leukocytes, no cytochrome b558 was
detected on the cell surface. Unlike normal leuko-
cytes, most of the gp91-phox in leukocytes from pa-
tient 3 remained sensitive to Endo-H digestion, sug-
gesting that this mutant gp91-phox is retained in the
ER. As a membrane-bound heterodimer, cytochrome
b558 is formed after gp91-phox and p22-phox assem-
ble in the ER and tra⁄c to lysosomes/endosomes or
the cell surface. When gp91-phox production is de-
fective in X-linked CGD, p22-phox also cannot exit
the ER and is subject to degradation together with
gp91-phox. The level of p22-phox in patient 3 was
consistently more abundant than in patients 1 and
2, but less than in normal controls. This implies
that the mutant gp91-phox retained in the ER stabil-
izes p22-phox through protein^protein interaction, a
process reported to be dependent on correct incorpo-
ration of heme into gp91-phox [20]. Although the
mutation of His-338 to Tyr leads to FAD depletion
of cytochrome b558 [14], the defective protein appears
to maintain the appropriate conformation to interact
with and stabilize p22-phox. A previous report sug-
gested that the association between gp91-phox and
p22-phox occurs in the post-ER compartment [21].
However, our data in untransfected human leuko-
cytes imply that the stabilization of p22-phox by
gp91-phox is initiated before gp91-phox becomes
Endo-H resistant (i.e. within the ER, in the ER-to-
Golgi intermediate compartment, or in the cis-Gol-
gi). This result is in accordance with a recent report
revealing the association between gp91-phox and
p22-phox without N-glycosylation of the former
[20]. Our calnexin co-immunoprecipitation experi-
ments, in accordance with previous studies [21],
showed that the immature 60^65 kDa form of
gp91-phox (gp65) is the predominant form in the
ER. In p22-phox-de¢cient CGD leukocytes, abun-
dant expression of this immature 60^65 kDa gp91-
phox suggests that successful association of gp91-
phox with p22-phox is essential for further matura-
tion of gp91-phox [22,23]. In addition to gp65, anti-
gp91-phox reactive protein species resolved in the
molecular mass range of 90^130 kDa were observed
in both the whole cell lysates and in the co-immuno-
precipitation with calnexin. Based on their sensitivity
to Endo-H digestion, we believe these protein spe-
cies, together with gp65, represent variably glycosy-
lated forms of high mannose gp91-phox. Our analysis
of patient 3 suggests that FAD binding, in addition
to the association with p22-phox, is necessary for
gp91-phox to dissociate from calnexin, exit the ER,
be processed in the Golgi complex, and travel to the
plasma or speci¢c granule membranes.
Unexpectedly, p22-phox appeared to be associated
with calnexin even in the absence of gp91-phox in
patient 1 (Fig. 5). As calnexin is believed to associate
with glycoproteins by binding to monoglucosylated
trimming intermediates of the N-linked core glycans
[24], unglycosylated p22-phox may associate with cal-
nexin through calnexin-bound glycoproteins other
than gp91-phox.
In summary, by analyzing three patients with X-
CGD, we found that di¡erent mechanisms underlie
the common phenotype of an absence of mature,
membrane-bound cytochrome b558 in leukocytes
from these patients. Degradation of the aberrant
molecules occurs at the levels of mRNA, nascent
peptide and chaperon-bound protein complex. Mo-
lecular quality control machinery thus appears to
play an important role in the pathogenesis of
CGD, not only in the X910 but also in the X913
form of the disease. This mechanism is likely to
contribute to phenotypes caused by mutations in
other inherited diseases that a¡ect leukocytes. As
cells of leukocyte lineage are among the important
targets of gene therapy [25], unraveling the molec-
ular quality control mechanisms is not only impor-
tant for understanding inherited diseases but also
for e¡ective manipulation of gene expression in hu-
man leukocytes.
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